Maito Suoh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maito Suoh has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jacob George
Westmead Hospital
6 shared publications Mohammed Eslam
Storr Liver Centre, The Westmead Institute for Medical Research Westmead New South Wales Australia
5 shared publications- Saeed Esmaili
Storr Liver Centre, The Westmead Institute for Medical Research Westmead New South Wales Australia
5 shared publications - Mohammed Eslam
Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, Australia
2 shared publications Saeed Esmaili
Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 2145, Australia
2 shared publicationsJacob George
Storr Liver Centre The Westmead Institute for Medical Research Westmead New South Wales Australia
1 shared publication
Latest Publications
- 15 July 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (8) , e70206
Nationwide Socioeconomic Evaluation of Direct‐Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023
Interferon‐free direct‐acting antivirals (DAAs), which are highly effective in eliminating hepatitis C virus (HCV), became available in Japan in 2014. This study aimed to estimate the nationwide socioeconomic outcomes of DAA therapy in Japan using publicly available records, including data from the hepatitis subsidy program and universal healthcare claims between fiscal years 2014 and 2023. Based on the standard dose of each DAA regimen, approximately 300,000 people were estimated to have been treated with DAA therapy by 2023, with a cumulative drug cost of at least 1.23 trillion Japanese yen (10.8 billion United States dollars). The main indication for DAA therapy was the initial treatment of chronic HCV infection without cirrhosis. The estimated cost and number of treated people peaked in 2015, followed by a declining trend. For most DAA regimens, annual prescriptions were the greatest in the same or the following year of approval. Sofosbuvir/ledipasvir and glecaprevir/pibrentasvir were the two most common regimens. The age of people treated with DAA therapy shifted towards younger people during the survey period, particularly in males. While the estimated prevalence of people treated with DAA therapy was higher in Western Japan, the estimated number of treated people and population in each prefecture showed a linear association ( p < 0.001). Despite the large economic impact, the rapid uptake of DAA therapy suggests an active program of case finding and treatment with the goal of HCV elimination in Japan. Whereas the demographics of people receiving DAA therapy changed over time, treatments were provided uniformly across the nation.
- 15 July 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (8) , e70206
Nationwide Socioeconomic Evaluation of Direct‐Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023
Interferon‐free direct‐acting antivirals (DAAs), which are highly effective in eliminating hepatitis C virus (HCV), became available in Japan in 2014. This study aimed to estimate the nationwide socioeconomic outcomes of DAA therapy in Japan using publicly available records, including data from the hepatitis subsidy program and universal healthcare claims between fiscal years 2014 and 2023. Based on the standard dose of each DAA regimen, approximately 300,000 people were estimated to have been treated with DAA therapy by 2023, with a cumulative drug cost of at least 1.23 trillion Japanese yen (10.8 billion United States dollars). The main indication for DAA therapy was the initial treatment of chronic HCV infection without cirrhosis. The estimated cost and number of treated people peaked in 2015, followed by a declining trend. For most DAA regimens, annual prescriptions were the greatest in the same or the following year of approval. Sofosbuvir/ledipasvir and glecaprevir/pibrentasvir were the two most common regimens. The age of people treated with DAA therapy shifted towards younger people during the survey period, particularly in males. While the estimated prevalence of people treated with DAA therapy was higher in Western Japan, the estimated number of treated people and population in each prefecture showed a linear association ( p < 0.001). Despite the large economic impact, the rapid uptake of DAA therapy suggests an active program of case finding and treatment with the goal of HCV elimination in Japan. Whereas the demographics of people receiving DAA therapy changed over time, treatments were provided uniformly across the nation.
- 13 June 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (10) , 1564-1567
Nationwide Trends of Noninvasive Tests for Liver Fibrosis in Japan Between 2014 and 2023
- 13 June 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (10) , 1564-1567
Nationwide Trends of Noninvasive Tests for Liver Fibrosis in Japan Between 2014 and 2023
- 28 February 2026
- Published by Springer Nature in Hepatology International
- Vol. 20 (4) , 1-4
Assessing pricing and affordability of HBV treatment in Japan
- 28 February 2026
- Published by Springer Nature in Hepatology International
- Vol. 20 (4) , 1-4
Assessing pricing and affordability of HBV treatment in Japan
- Open Access
- 23 September 2025
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (2) , 102118
Drug pricing for hepatitis B and C in Australia and Japan
- 23 September 2025
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (2) , 102118
Open AccessDrug pricing for hepatitis B and C in Australia and Japan
- 2 April 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (2) , 480-482
Reply to “Metabolic (dysfunction)-associated fatty liver disease metrics and contributions: Correspondence”
- 2 April 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (2) , 480-482
Reply to “Metabolic (dysfunction)-associated fatty liver disease metrics and contributions: Correspondence”
- 17 December 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (4) , e201-e203
Transitions in the nomenclatures for fatty liver disease
- 17 December 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (4) , e201-e203
Transitions in the nomenclatures for fatty liver disease
- Open Access
- 16 October 2024
- Published by Springer Nature in Hepatology International
- Vol. 18 (6) , 1740-1755
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Background: The international consensus to revise non-alcoholic fatty liver disease to metabolic (dysfunction)-associated fatty liver disease (MAFLD) in 2020 attracted significant attention. The impact of the MAFLD definition on the research community has not been objectively assessed. We conducted an analysis of systematically collected literature on MAFLD to understand its research impact. Methods: From PubMed, Web of Science, and Scopus, the literature adopting MAFLD, written in English, and published from 2020 to 10 October 2023 was collected. The publication metrics, including publication counts, publishing journals, author countries, author keywords, and citation information, were analyzed to evaluate the research impact and key topics on MAFLD. Results: 1469 MAFLD-related papers were published in 434 journals with a steady increase in the number. The intense publishing and citations activity on MAFLD indicates the large impact of the redefinition. Topic assessment with keyword and citation analysis revealed a transition from the proposal and discussion of the redefinition to clinical characterization of MAFLD with a focus on metabolic dysfunction. Moreover, the diagnostic criteria for MAFLD showed better performance in predicting hepatic and extrahepatic outcomes compared to NAFLD. The publications were from 99 countries with evidence of strong regional and global collaboration. Multiple international societies and stakeholders have endorsed MAFLD for its utility in clinical practice, improving patient management and promoting multidisciplinary care, while alleviating stigma. Conclusion: This survey provides a quantitative measure of the considerable international impact and contributions of the MAFLD definition towards liver research and as part of the spectrum of cardiometabolic disorders.
- 16 October 2024
- Published by Springer Nature in Hepatology International
- Vol. 18 (6) , 1740-1755
Open AccessMetabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Background: The international consensus to revise non-alcoholic fatty liver disease to metabolic (dysfunction)-associated fatty liver disease (MAFLD) in 2020 attracted significant attention. The impact of the MAFLD definition on the research community has not been objectively assessed. We conducted an analysis of systematically collected literature on MAFLD to understand its research impact. Methods: From PubMed, Web of Science, and Scopus, the literature adopting MAFLD, written in English, and published from 2020 to 10 October 2023 was collected. The publication metrics, including publication counts, publishing journals, author countries, author keywords, and citation information, were analyzed to evaluate the research impact and key topics on MAFLD. Results: 1469 MAFLD-related papers were published in 434 journals with a steady increase in the number. The intense publishing and citations activity on MAFLD indicates the large impact of the redefinition. Topic assessment with keyword and citation analysis revealed a transition from the proposal and discussion of the redefinition to clinical characterization of MAFLD with a focus on metabolic dysfunction. Moreover, the diagnostic criteria for MAFLD showed better performance in predicting hepatic and extrahepatic outcomes compared to NAFLD. The publications were from 99 countries with evidence of strong regional and global collaboration. Multiple international societies and stakeholders have endorsed MAFLD for its utility in clinical practice, improving patient management and promoting multidisciplinary care, while alleviating stigma. Conclusion: This survey provides a quantitative measure of the considerable international impact and contributions of the MAFLD definition towards liver research and as part of the spectrum of cardiometabolic disorders.